{"entity":{"id":"nct06974812","kind":"trial","name":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of IBI3014 in advanced solid tumours, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.","summary":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov record last updated 2026-01-29: recruiting. Enrollment is planned at 250 participants. Primary completion is estimated at 2026-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014, IBI3014. Registered primary measures: The Safety profile of patients in Phase 1 dose escalation part、Phase 1 dose expansion and Phase 2 dose optimization; Dose limiting toxicity (DLT) of IBI3014 in Phase 1 dose escalation; ORR per RECIST v1.1 in Phase 1 dose expansion and Phase 2 dose optimization.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06974812","url":"https://clinicaltrials.gov/study/NCT06974812"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["trop2"],"drugs":[],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-01-29: recruiting. Enrollment is planned at 250 participants. Primary completion is estimated at 2026-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06974812","phase":"1/2","setting":"IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","participation":[{"nct":"NCT06974812","source":"https://clinicaltrials.gov/study/NCT06974812","fetchedAt":"2026-10-07T16:55:20.203Z","studySha256":"e67199caa21eff11ec4ac3699da3b3f2628de2e5ecde2a2817cb086e64c7e8d1","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-29","leadSponsor":"Innovent Biologics (Suzhou) Co. Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":250,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":3,"countries":["China"]}],"started":"2025-04-18","startedType":"actual","enrolled":250,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06974812/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}],"drug":[{"id":"ibi3014","kind":"drug","name":"IBI3014","route":"/drugs/ibi3014/"}]}}